Pricing Log in Create free account
Saturday 7 November 2026 Export AGIO’s income statement to Excel — free account

Agios Pharmaceuticals, Inc.

AGIO Healthcare Biotechnology

Agios Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $54.0 million, up 48.0% from fiscal 2024.

Revenue
+330.0%
EPS
+38.8%
Free cash flow
+32.6%

Quarter to September 2026, against a year earlier

29.41 1.14 +4.03%
Market cap
$1.7B
P/E
0.0×
Fwd P/E
−5.1×
Dividend yield
—
F-score
3/9
Altman Z
8.12
Beneish M
−1.72
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 4.80
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 5 1 — 7 6 — — 1 1 — 2 —
Insider Ownership 2.44%

Capital & Financial Ratios $m

Size
Market Cap 1,690.00
Revenue ttm 140.84
Net income ttm (372.90)
Free cash flow ttm (335.97)
Net debt Q (630.01)
Valuation
P/E 0.00
Forward P/E (5.10) (negative: loss-making)
Price / sales 12.39 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 1.78
Financial health
Current ratio Q 9.69 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q —
Growth
Revenue growth Q +330.01% (above 0%: growing)
Operating income growth Q +33.98% (above 0%: growing)
EPS, this year +19.55% (at or above 15%: strong)
EPS, next year A +38.40% (at or above 15%: strong)
Revenue, next year A +227.98% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +40.16% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 7.9×, against a ten-year median of 21.8×; over the ten years it ranged from 1.2× in 2022 to 107× in 2018.
P/S against its own 10 years 5.98%
10-year low 10-year high
P/B against its own 10 years 38.16%
10-year low 10-year high
EV/Sales against its own 10 years 11.55%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 777 894 854 630
Receivables 3 4 11 —
Inventory 19 28 33 —
Other — — — —
834 966 942 752
2023 2024 2025 Q'26
Payables 10 17 18 20
ST’ Debt — — — —
Other — — — —
68 81 82 78

Compound Annual Growth %

10y 5y 3y
Sales (1.89%) (14.45%) 55.97%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 13.21% 24.46% 2.72%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −1.32 Actual −1.09

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 −1.97 −1.85 Beat by 0.12
Q1 FY26 −1.81 −1.69 Beat by 0.12
Q2 FY26 −1.86 −1.69 Beat by 0.17
Q3 FY26 −1.32 −1.09 Beat by 0.23
Q4 FY26 −1.30 — Reports 11 February 2027

EPS $

Mar Jun Sep Dec Year
’26 (1.69) (1.69) (1.09) — —
’25 (1.55) (1.93) (1.78) (1.85) (7.12)
’24 (1.45) (1.69) 16.22 (1.74) 11.64
’23 (1.47) (1.51) (1.64) (1.72) (6.33)
’22 (1.74) (1.68) (1.49) 0.67 (4.23)
’21 26.95 (1.41) (1.56) (1.74) 26.55
’20 (0.59) (1.31) (1.43) (1.41) (4.74)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 21 45 55 — —
’25 9 12 13 20 54
’24 8 9 9 11 36
’23 6 7 7 7 27
’22 1 6 4 4 14
’20 87 37 35 44 203
’19 30 26 26 35 118
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (119) (57) (59) — —
’25 (111) (77) (88) (96) (373)
’24 (100) (73) (84) (133) (390)
’23 (95) (67) (62) (72) (296)
’22 (98) (74) (71) (66) (309)
’21 (121) (117) (85) (84) (407)
’20 (105) (68) (68) (49) (291)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (120) (59) (60) — —
’25 (112) (78) (90) (97) (377)
’24 (100) (73) (85) (134) (391)
’23 (95) (67) (61) (73) (296)
’22 (101) (76) (71) (65) (313)
’21 (122) (118) (85) (89) (413)
’20 (110) (72) (73) (50) (305)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.6
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 70 43 94 118 203 — 14 27 36 54 141 (2.8%) 177 347 516 +112.1%
Gross margin, % 100.00 100.00 98.52 84.79 (9.24) 0.00 88.03 89.26 88.59 88.26 93.81 (11.7) pt
EBT (198) (315) (346) (301) (329) (357) (232) (352) 718 (414) (412) +8.5%
EBT margin, % (283.97) (731.60) (366.61) (255.62) (162.06) 0.00 (1,627.82) (1,312.63) 1,967.15 (765.89) 0.00 (481.9) pt
Net income (198) (315) (346) (411) (327) 1,605 (232) (352) 674 (413) (373) +8.5%
Per share, $
Per share, $ Revenue 1.79 0.92 1.64 1.97 2.95 0.00 0.26 0.48 0.64 0.93 2.36 (7.0%)
Earnings (5.07) (6.75) (6.03) (6.86) (4.74) 26.55 (4.23) (6.33) 11.86 (7.12) (6.32) +3.8%
Cash flow 0.99 (6.12) (5.30) (6.18) (4.21) (6.74) (5.65) (5.32) (6.86) (6.43) (5.56) n/m
Capex (0.25) (0.10) (0.12) (0.20) (0.20) (0.09) (0.07) 0.01 (0.03) (0.07) (0.07) (12.7%)
Free cash flow 0.73 (6.22) (5.42) (6.38) (4.42) (6.83) (5.72) (5.31) (6.89) (6.51) (5.63) n/m
Book value 9.16 8.06 11.97 10.68 5.79 21.37 20.09 14.57 27.13 20.58 16.40 +9.4%
Shares, m 39 47 57 60 69 60 55 56 57 58 59 +4.5%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 — 0.00 0.00 2.79 0.00 0.00 0.3
P/S 24.20 64.81 28.05 24.30 14.71 — 105.92 47.37 51.15 29.21 12.39 43.3
P/B 4.72 7.42 3.85 4.47 7.48 — 1.37 1.57 1.21 1.32 1.78 3.7
EV/Sales 16.45 54.95 21.85 19.51 11.90 — 50.95 18.41 26.67 13.40 7.92 26.0
EV/FCF 40.13 (8.15) (6.62) (6.01) (7.93) — (2.31) (1.67) (2.49) (1.92) (3.32) 0.3
Cash, $m
Cash, $m Operating cash flow 39 (285) (304) (371) (291) (407) (309) (296) (390) (373) (332) n/m
Capex (10) (5) (7) (12) (14) (6) (4) 0 (2) (4) (4) (8.8%)
Free cash flow 29 (290) (311) (383) (305) (413) (313) (296) (391) (377) (336) n/m
Balance, $m
Balance, $m Working capital 471 350 520 519 542 1,004 770 766 884 860 675 +6.9%
Net debt (541) (424) (585) (564) (573) (1,020) (783) (777) (894) (854) (630) +5.2%
Shareholders’ equity 359 376 688 641 400 1,292 1,101 811 1,541 1,193 979 +14.3%
Returns, %
Returns, % ROA (38.20) (51.02) (46.99) (47.05) (37.55) 140.11 (17.32) (32.36) 51.82 (27.89) (30.44) +10.3 pt
ROIC 0.00 0.00 (221.60) (258.99) 0.00 (86.88) (76.54) (717.72) (41.11) (87.12) (75.02) (87.1) pt
ROE (56.41) (85.73) (65.10) (61.97) (62.95) 189.74 (19.37) (36.83) 57.29 (30.20) (32.95) +26.2 pt
People
People Employees 287 382 482 536 562 392 393 386 488 540 — +7.3%
Revenue/emp, $m 0.24 0.11 0.20 0.22 0.36 0.00 0.04 0.07 0.07 0.10 — (9.4%)
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Agios Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
STOK Stoke Therapeutics, Inc. $1.7B — (loss-making) — (loss-making) +5.86% (above 0%: growing) n/m −114.89% (below 0%: shrinking) 100.00% (686.94%) Compare
AGIO Agios Pharmaceuticals, Inc. $1.7B — (loss-making) — (loss-making) +330.01% (above 0%: growing) n/m +32.64% (above 0%: growing) 95.44% (139.32%)
ZBIO Zenas BioPharma, Inc. $1.7B — (loss-making) — (loss-making) — n/m −41.00% (below 0%: shrinking) 100.00% (1,034.09%) Compare
LYCA Lycia Therapeutics Inc. $1.7B — — — — — — — Compare
NRIX Nurix Therapeutics, Inc. $1.6B 6.1× 5.5× +8,426.27% (above 0%: growing) n/m +1,122.10% (above 0%: growing) 100.00% 83.12% Compare
ABSI Absci Corporation $1.6B — (loss-making) — (loss-making) −46.37% (below 0%: shrinking) n/m −71.74% (below 0%: shrinking) 100.00% (10,741.51%) Compare
GENB Generate Biomedicines, Inc. $1.6B — (loss-making) — (loss-making) — n/m −224.24% (below 0%: shrinking) 100.00% (1,134.21%) Compare
NVAX Novavax, Inc. $1.6B — (loss-making) 110× −3.05% (below 0%: shrinking) n/m −189.09% (below 0%: shrinking) 65.61% (45.80%) Compare
SLS SELLAS Life Sciences Group, Inc. $1.6B — (loss-making) — (loss-making) −57.10% (below 0%: shrinking) n/m −3.52% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $1.6B — — −3.05% — −71.74% 100.00% (686.94%)

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 24 April 2026

Ownership

Directors and executive officers, together 5.40%
The Vanguard Group 9.40%
Entities affiliated with Farallon Capital Partners, L.P. 8.70%
BlackRock, Inc. 7.60%
State Street Corporation 5.20%
Armistice Capital, LLC 5.10%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Agios Pharmaceuticals, Inc. (AGIO) Latest News

6 Nov

Impact 4 · · GuruFocus.com

5 Nov

Impact 4 · · Moby
Impact 4 · · GlobeNewswire
Impact 3 · · MarketBeat
Impact 3 · · Zacks

4 Nov

Impact 3 · · Simply Wall St.

30 Oct

Impact 3 · · TIKR
Impact 3 · · GlobeNewswire

29 Oct

Impact 3 · · Zacks

20 Oct

Impact 4 · · Simply Wall St.

9 Oct

Impact 4 · · Simply Wall St.
Impact 3 · · Simply Wall St.

6 Oct

Impact 4 · · Zacks

2 Oct

Impact 4 · · Zacks

30 Jul

Impact 4 · transcript
Impact 3 · · MarketBeat transcript
Impact 3 · earnings

29 Jul

Impact 4 ·

22 Jul

Impact 4 ·

21 Jul

Impact 4 · · clinicaltrialsarena.com
Impact 4 · · biopharmadive.com
Impact 3 · · Stocktwits
Impact 3 ·
Impact 3 · · InvestorsHub
Impact 3 ·

10 Jul

Impact 3 · · The Motley Fool

9 Jul

Impact 4 ·
Impact 4 ·

8 Jul

Impact 4 ·

7 Jul

Impact 4 · · The Motley Fool
stockrow.com/AGIO · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com